Reata Pharmaceuticals, Inc. Company News: Berger Montague Investigates Securities Fraud Allegations Against Reata Pharmaceuticals, Inc. (RETA)

Philadelphia, Pennsylvania--(Newsfile Corp. - December 22, 2021) - Berger Montague is investigating securities fraud allegations on behalf of investors who purchased the securities of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA).

If you purchased Reata securities, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Michael Dell'Angelo at mdellangelo@bm.net or (215) 875-3080.

Whistleblowers: Anyone with non-public information regarding Reata is encouraged to confidentially assist Berger Montague's investigation or take advantage of the SEC Whistleblower program. Under this program, whistleblowers who provide original information may receive rewards totaling up to thirty percent (30%) of recoveries obtained by the SEC. For more information, contact us.

The firm's investigation is focused on the Company's statements about its Phase 3 clinical study (CARDINAL) of bardoxolone methyl in patients with chronic kidney disease caused by Alport syndrome and the related new drug application ("NDA").

In the past, Reata and its executives represented that the CARDINAL study showed that bardoxolone met its primary and secondary endpoints, and therefore supported the submission of the NDA to the FDA.

However, on December 6, 2021, the FDA released a set of briefing documents ahead of the December 8th Cardiovascular and Renal Drugs Advisory Committee meeting. These documents revealed that during meetings with the FDA that occurred in at least January, September, and December 2020, the FDA took issue with Reata's proposed approach toward its NDA submission, as well as with the interpretability of certain findings, the amount of missing data, and the integrity of the trial data.

On this news, the price of Reata shares fell $29.77 per share - or 37.8% - to close at $48.92 per share on December 6, 2021.

Berger Montague, with offices in Philadelphia, Minneapolis, Washington, D.C., and San Diego, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

Contacts
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bm.net

Michael Dell'Angelo, Executive Shareholder
Berger Montague
(215) 875-3080
mdellangelo@bm.net

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/108344